PL2982982T3 - Sposób badania przesiewowego związków przy użyciu błonowego STIM1 - Google Patents

Sposób badania przesiewowego związków przy użyciu błonowego STIM1

Info

Publication number
PL2982982T3
PL2982982T3 PL14290232T PL14290232T PL2982982T3 PL 2982982 T3 PL2982982 T3 PL 2982982T3 PL 14290232 T PL14290232 T PL 14290232T PL 14290232 T PL14290232 T PL 14290232T PL 2982982 T3 PL2982982 T3 PL 2982982T3
Authority
PL
Poland
Prior art keywords
screening compounds
membrane stim1
stim1
membrane
screening
Prior art date
Application number
PL14290232T
Other languages
English (en)
Polish (pl)
Inventor
Yves Renaudineau
Olivier Mignen
Miguel Burgos
Jacques Olivier Pers
Tinhinane Fali
Original Assignee
Centre Hospitalier Regional Et Univ De Brest
Inst Nat Sante Rech Med
Univ De Bretagne Occidentale U B O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre Hospitalier Regional Et Univ De Brest, Inst Nat Sante Rech Med, Univ De Bretagne Occidentale U B O filed Critical Centre Hospitalier Regional Et Univ De Brest
Publication of PL2982982T3 publication Critical patent/PL2982982T3/pl

Links

Classifications

    • G01N33/57505
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/04Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • G01N2500/10Screening for compounds of potential therapeutic value involving cells
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/10Musculoskeletal or connective tissue disorders
    • G01N2800/101Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104Lupus erythematosus [SLE]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL14290232T 2014-08-06 2014-08-06 Sposób badania przesiewowego związków przy użyciu błonowego STIM1 PL2982982T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14290232.9A EP2982982B1 (en) 2014-08-06 2014-08-06 Method of screening of compounds using membrane STIM1

Publications (1)

Publication Number Publication Date
PL2982982T3 true PL2982982T3 (pl) 2018-03-30

Family

ID=51398585

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14290232T PL2982982T3 (pl) 2014-08-06 2014-08-06 Sposób badania przesiewowego związków przy użyciu błonowego STIM1

Country Status (11)

Country Link
US (2) US20170219588A1 (enExample)
EP (2) EP2982982B1 (enExample)
JP (2) JP6754751B2 (enExample)
CN (2) CN110051836B (enExample)
CA (1) CA2952159C (enExample)
DK (1) DK2982982T3 (enExample)
ES (1) ES2654674T3 (enExample)
NO (1) NO2982982T3 (enExample)
PL (1) PL2982982T3 (enExample)
PT (1) PT2982982T (enExample)
WO (1) WO2016020274A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3714943A1 (en) 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
EP3715848A1 (en) * 2019-03-25 2020-09-30 Université de Bretagne Occidentale (U.B.O.) Substance interacting with c terminal fragment of the stim1 fraction localized to the plasma membrane of the cells, for its use in the treatment of cancers, and in screening and diagnostic methods
EP3714942A1 (en) * 2019-03-25 2020-09-30 Université De Bretagne Occidentale - UBO Monoclonal antibody against stim1
US20240083990A1 (en) * 2021-01-26 2024-03-14 Universite Brest Bretagne Occidentale Novel stim1 splicing variants and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2341484T3 (es) * 2005-05-20 2010-06-21 Genentech, Inc. Pretratamiento de una muestra biologica de un sujeto que sufre una enfermedad autoinmune.
WO2008148108A1 (en) * 2007-05-24 2008-12-04 Calcimedica, Inc. Calcium channel proteins and uses thereof
US20160169868A9 (en) * 2007-05-24 2016-06-16 Calcimedica, Inc. Calcium channel proteins and uses thereof
EP2472262A3 (en) * 2007-07-10 2012-10-17 Immune Disease Institute, Inc. Stromal interacting molecule knockout mouse and uses thereof
WO2009021338A1 (en) * 2007-08-15 2009-02-19 UNIVERSITé DE SHERBROOKE Alternative splicing gene variants in cancer detection
AU2008299220B2 (en) * 2007-09-10 2011-07-21 Calcimedica, Inc. Compounds that modulate intracellular calcium
EP2103311A1 (en) * 2008-03-20 2009-09-23 CSL Behring GmbH The calcium sensor STIM1 is essential for pathological thrombus formation
WO2010099401A1 (en) * 2009-02-26 2010-09-02 The Board Of Trustees Of The Leland Stanford Junior University Calcium signaling modulators involving stim and orai proteins
US8993612B2 (en) * 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
US20160194393A1 (en) * 2011-08-10 2016-07-07 Biommune Technologies Inc. Methods and compositions for modulating voltage-gated calcium channel function
CN102433383B (zh) * 2011-12-19 2015-07-08 上海吉凯基因化学技术有限公司 人stim1基因的用途及其相关药物

Also Published As

Publication number Publication date
NO2982982T3 (enExample) 2018-03-03
PT2982982T (pt) 2018-01-03
JP2019214576A (ja) 2019-12-19
JP6861246B2 (ja) 2021-04-21
CA2952159A1 (en) 2016-02-11
EP3177929A1 (en) 2017-06-14
US20170219588A1 (en) 2017-08-03
JP6754751B2 (ja) 2020-09-16
JP2017531164A (ja) 2017-10-19
EP2982982B1 (en) 2017-10-04
CN110051836A (zh) 2019-07-26
ES2654674T3 (es) 2018-02-14
CN106716130B (zh) 2019-03-29
EP2982982A1 (en) 2016-02-10
US20190154690A1 (en) 2019-05-23
CA2952159C (en) 2022-08-30
DK2982982T3 (en) 2018-01-08
WO2016020274A1 (en) 2016-02-11
CN110051836B (zh) 2023-05-26
EP3177929B1 (en) 2018-05-09
CN106716130A (zh) 2017-05-24

Similar Documents

Publication Publication Date Title
IL249981A0 (en) Method
IL255100A0 (en) Method of preparing a faecal microbiota sample
GB201402318D0 (en) Method for materials analysis
DK3122444T3 (da) Fremgangsmåde til fremstilling af membraner
FI20146127A7 (fi) Prosessi hiilivetyjen valmistamiseksi
FR3028872B1 (fr) Procede de fractionnement
FI20145442A7 (fi) Menetelmä kartongin valmistamiseksi
DK3125898T3 (da) Farmakofor til trail-induktion
DK3152332T3 (da) Fremgangsmåde til at analysere methylering
LT3233813T (lt) Į oksatiaziną panašių junginių gavimo būdai
FI20146115A7 (fi) Menetelmä kemikaalitestausta varten
IL251952B (en) Improved method for seed priming
DK3114053T3 (da) Maskine til separation af elementer
PL2982982T3 (pl) Sposób badania przesiewowego związków przy użyciu błonowego STIM1
DK3237433T3 (da) Fremgangsmåde til fremstilling af protein
FI20145435A7 (fi) Menetelmä kuparia sisältävän materiaalin konvertoimiseksi
DK3131567T3 (da) Fremgangsmåde til fremstilling af GNRH-holdig gel
DK3120699T3 (da) Filter under grus til et akvarium
DK3053446T3 (da) Fremgangsmåde til fremstilling af schweizerost
FR3026409B1 (fr) Procede de criblage de molecules interferentes
TH1601000051B (th) วิธีการสำหรับการผลิตพอลิไดออกโซเลน
TH1601002609A (th) กระบวนการทำอะดามันทานาไมด์
TH1501004492A (th) วิธีสำหรับทำสารประกอบ pnpnh ดิบให้บริสุทธิ์
FR3029201B1 (fr) Procede de metathese
TH1601002561A (th) สารประกอบชนิดใหม่สำหรับการควบคุมสัตว์ขาปล้อง